Unknown

Dataset Information

0

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.


ABSTRACT: The targeted inactivation of oncogenes offers a rational therapeutic approach for the treatment of cancer. However, the therapeutic inactivation of a single oncogene has been associated with tumor recurrence. Therefore, it is necessary to develop strategies to override mechanisms of tumor escape from oncogene dependence. We report here that the targeted inactivation of MYC is sufficient to induce sustained regression of hematopoietic tumors in transgenic mice, except in tumors that had lost p53 function. p53 negative tumors were unable to be completely eliminated, as demonstrated by the kinetics of tumor cell elimination revealed by bioluminescence imaging. Histological examination revealed that upon MYC inactivation, the loss of p53 led to a deficiency in thrombospondin-1 (TSP-1) expression, a potent antiangiogenic protein, and the subsequent inability to shut off angiogenesis. Restoration of p53 expression in these tumors re-established TSP-1 expression. This permitted the suppression of angiogenesis and subsequent sustained tumor regression upon MYC inactivation. Similarly, the restoration of TSP-1 alone in p53 negative tumors resulted in the shut down of angiogenesis and led to sustained tumor regression upon MYC inactivation. Hence, the complete regression of tumor mass driven by inactivation of the MYC oncogene requires the p53-dependent induction of TSP-1 and the shut down of angiogenesis. Notably, overexpression of TSP-1 alone did not influence tumor growth. Therefore, the combined inactivation of oncogenes and angiogenesis may be a more clinically effective treatment of cancer. We conclude that angiogenesis is an essential component of oncogene addiction.

SUBMITTER: Giuriato S 

PROVIDER: S-EPMC1637571 | biostudies-literature | 2006 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.

Giuriato Sylvie S   Ryeom Sandra S   Fan Alice C AC   Bachireddy Pavan P   Lynch Ryan C RC   Rioth Matthew J MJ   van Riggelen Jan J   Kopelman Andrew M AM   Passegué Emmanuelle E   Tang Flora F   Folkman Judah J   Felsher Dean W DW  

Proceedings of the National Academy of Sciences of the United States of America 20061020 44


The targeted inactivation of oncogenes offers a rational therapeutic approach for the treatment of cancer. However, the therapeutic inactivation of a single oncogene has been associated with tumor recurrence. Therefore, it is necessary to develop strategies to override mechanisms of tumor escape from oncogene dependence. We report here that the targeted inactivation of MYC is sufficient to induce sustained regression of hematopoietic tumors in transgenic mice, except in tumors that had lost p53  ...[more]

Similar Datasets

| S-EPMC1941831 | biostudies-other
| S-EPMC2991103 | biostudies-literature
2012-09-06 | E-GEOD-40606 | biostudies-arrayexpress
| S-EPMC5008323 | biostudies-literature
2012-09-06 | GSE40606 | GEO
| S-EPMC1945092 | biostudies-literature
| S-EPMC7533841 | biostudies-literature
2016-06-14 | E-GEOD-77482 | biostudies-arrayexpress
| S-EPMC4372114 | biostudies-literature
| 2161751 | ecrin-mdr-crc